Ontology highlight
ABSTRACT:
SUBMITTER: Kim CS
PROVIDER: S-EPMC5502144 | biostudies-literature | 2017 Jul
REPOSITORIES: biostudies-literature
Kim Choung Soo CS Choi Young Deuk YD Lee Sang Eun SE Lee Hyun Moo HM Ueda Takeshi T Yonese Junji J Fukagai Takashi T Chiong Edmund E Lau Weber W Abhyankar Sarang S Theeuwes Ad A Tombal Bertrand B Beer Tomasz M TM Kimura Go G
Medicine 20170701 27
<h4>Background</h4>Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In PREVAIL, an international, phase III, double-blind, placebo-controlled trial, enzalutamide significantly reduced the risk of radiographic progression by 81% (hazard ratio [HR], 0.19; P < .0001) and reduced the risk of death by 29% (HR, 0.71; P < .0001) compared with placebo in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.<h4>Methods</h ...[more]